Drug updated on 10/30/2024
| Dosage Form | Opthalmic solution (topical; netarsudil 0.2 mg/mL [0.02%] and latanoprost 0.05 mg/mL [0.005%]) |
| Drug Class | Rho kinase inhibitors and prostaglandin F2α analogues |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Latest News
Summary
- This summary is based on the review of three systematic review(s)/meta-analysis(es). [1-3]
- The fixed-dose combination (FDC) of netarsudil and latanoprost reduced intraocular pressure (IOP) more than latanoprost monotherapy, with a mean reduction difference of -2.41 mmHg (95% CI: -2.95 to -1.87) after 2 weeks and -1.77 mmHg (95% CI: -2.31 to -1.87) after 4 to 6 weeks. A meta-analysis of 3 trials found an additional mean IOP reduction of 1.64 mmHg (95% CI: -2.16 to -1.11) compared to latanoprost alone.
- FDC reduced IOP more effectively than netarsudil monotherapy, with a pooled mean reduction difference of 2.66 mmHg (95% CI: -2.98 to -2.35). Latanoprost monotherapy was also more effective than netarsudil, with a mean difference of 0.95 mmHg (95% CI: 0.43 to 1.47) after 4 to 6 weeks.
- Netarsudil reduced IOP more than placebo by 3.11 mmHg (95% CI: 2.59 to 3.62) but was less effective than timolol, with a mean difference of 0.66 mmHg (95% CI: 0.41 to 0.91) favoring timolol.
- The risk of conjunctival hyperemia (CH) was significantly higher with netarsudil/latanoprost fixed-dose combination (FDC) and netarsudil monotherapy compared to latanoprost monotherapy at week 12 (Relative Ratios: 3.01 [95% CI: 1.95 to 4.66] for FDC and 2.33 [95% CI: 1.54 to 3.54] for netarsudil).
- Netarsudil and FDC therapies resulted in a higher incidence of adverse events (AEs) compared to latanoprost, with ocular AEs more frequent in netarsudil treatment than with placebo, latanoprost, or timolol. Serious AEs were not associated with netarsudil, and reported AEs were mild, transient, and reversible upon discontinuation.
- The studies included adult participants diagnosed with primary open-angle glaucoma (POAG), open-angle glaucoma (OAG), or ocular hypertension (OHT), all aged above 18 years, with no significant differences in effectiveness outcomes reported among subgroups based on age, gender, or comorbid conditions.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Rocklatan (netarsudil and latanoprost ophthalmic solution) Prescribing Information. | 2023 | Aerie Pharmaceuticals, Inc., Irvine, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Comparison of netarsudil/Latanoprost therapy with latanoprost monotherapy for lowering intraocular pressure: A systematic review and meta-analysis. | 2022 | Korean Journal of Ophthalmology |
| Efficacy and safety of netarsudil/latanoprost fixed-dose combination vs. monotherapy in open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis of randomized controlled trials. | 2022 | Frontiers in Medicine |
| Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension. | 2022 | The Cochrane Database of Systematic Reviews |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension. Technology appraisal guidance number TA1009. | 2024 | National Institute for Health and Care Excellence |
| Guidelines for the management of open-angle glaucoma: National Program Area Eye Diseases, National Working Group Glaucoma. | 2024 | Acta Ophthalmologica |